Apogee Therapeutics, Inc.

    • Market Cap $2.64B
    • PE -18
    • Debt $NaN
    • Cash $119.07M
    • EV $NaN
    • FCF $NaN

    Earnings

    loading chart...

    Sales & Net Margins

    loading chart...
    Earnings-$146.66M
    EBIT-$178.14M
    ROE-20%
    ROA-23%
    Equity$734.40M
    Growth Stability1
    PE-18.02
    PB3.6
    Price/Cash0.05
    Equity CAGR21%
    Earnings Growth YoY135%
    Earnings Growth QoQ45%
    Equity CAGR 5Y21%
    Equity CAGR 3Y21%
    Market Cap$2.64B
    Assets$776.29M
    Cash$119.07M
    Shares Outstanding54.47M
    Working Capital501.87M
    Current Ratio16.39
    Shares Growth 3y84%
    Equity Growth QoQ-5%
    Equity Growth YoY79%

    Assets & ROA

    loading chart...

    Stockholders Equity & ROE

    loading chart...
    Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

    SEC Filings

    Direct access to Apogee Therapeutics, Inc. (APGE) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

    • 2024
      • 10-Q Sep 30
      • 10-Q Jun 30
      • 10-Q Mar 31
    • 2023
      • 10-K Dec 31
      • 10-Q Sep 30
      • 10-Q Jun 30

    Sector Comparison

    How does Apogee Therapeutics, Inc. compare to its competitors?

    Loading chart...

    Peter Lynch's Chart

    This chart shows the current pricing of Apogee Therapeutics, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

    loading chart...

    Apogee Therapeutics, Inc. Discounted Cash Flow

    Fully customizable DCF calculator online for Apogee Therapeutics, Inc..

    0
    012345678910TV
    fcf$0$0$0$0$0$0$0$0$0$0$0$0
    DCF$0$0$0$0$0$0$0$0$0$0$0
    Value$0

    Competitiveness and MOAT

    High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

    Years12/202212/2023TTM
    Net Margins---
    ROA--23%-23%
    ROE--22%-20%

    Safety and Stability

    Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

    Years12/202212/2023TTM
    Debt over FCF---
    Debt over Equity---
    Growth Stability--1

    Growth

    Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

    Years12/202212/2023CAGR 5Y
    Revenue YoY growth---
    Earnings YoY growth-111%-
    Equity YoY growth--1K%21%
    FCF YoY growth---